Study of SBP-101 in Pancreatic Cancer

Summary

This phase 1 first-in-human study evaluates safety and tolerability of SBP-101 in subjects with previously treated pancreatic ductal adenocarcinoma and will identify the maximum tolerated dose (MTD). In addition, this study will also assess the pharmacokinetic (PK) profile and preliminary efficacy of SBP-101.

Timeline

Start

2016-01

Primary completion

2017-10

Completion

2017-10

Drugs

Indications